AMSBIO unveils StemFit® for Differentiation, a GMP-grade medium for differentiating human induced pluripotent stem (hiPS) and embryonic stem (hES) cells

AMSBIO has introduced its GMP-grade StemFit® for Differentiation, a medium designed for the differentiation of human induced pluripotent stem (hiPS) and embryonic stem (hES) cells.

This formulation, now compliant with Good Manufacturing Practices (GMP), is intended to support clinical applications by eliminating animal-derived components and minimizing immunogenic risks.

The company reports that StemFit® ensures lot-to-lot consistency under strict GMP guidelines. They say this provides a reliable solution for the reproducible expansion and differentiation of stem cell-derived tissues in clinical settings.

AMSBIO plans to transition all StemFit® formulations, including Basic03 and Basic04 CT, along with key proteins such as bFGF (basic Fibroblast Growth Factor) and Activin A, to GMP-grade versions by the end of 2025. This transition aims to enable laboratories to move from research to clinical manufacturing without the need to retest materials or adjust protocols, thereby reducing complexity and costs. The company has optimized manufacturing processes to minimize cost differences between research and GMP-grade products.

For further details: https://www.amsbio.com/stemfit-for-differentiation/

Similar stories

Encellin and Breakthrough T1D Planning Phase 1 of Immune-Protected Cell Therapy for Type 1 DiabetesSep 23, 2026Webinar: Scaling iPSC Therapies Without Scaling VariabilitySep 23, 2026Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell TherapySep 21, 2026Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy FacilitySep 21, 2026

Editor’s Picks

Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND SoonOct 20, 2026Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis TrialOct 18, 2026Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic AcidOct 18, 2026Novadip Secures €10.4M for Pivotal Phase 3 Bone Repair Cell Therapy TrialSep 21, 2026